Protocol Ledger

NCT06492291 · Phase III · ACTIVE NOT RECRUITING

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Interventional Phase III clinical trial protocol NCT06492291 sponsored by Merck & Co. in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-05 Enrollment: 3,000 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06492291
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,000 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06492291
Protocol FieldVerified Registry Value
NCT IdentifierNCT06492291
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment3,000 participants (ESTIMATED)
Registered Start Date2024-08-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06492291
Hospital Research SiteLocationSite Profile
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI